Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT04310709 2022-12-06

RENOBATE

Phase 2 Completed

42 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04718909 2022-11-10

REGSIN

Phase 2 Unknown

166 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

176 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04476329 2021-12-30

ReDos HCC

Phase 2 Terminated

7 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01774344 2020-08-20

RESORCE

Phase 3 Completed

573 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01003015 2015-04-03

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Phase 2 Completed

36 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

REVIVE

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

RELEVANT-HCC

RECOMEND

REPLACE

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

LEAF-02

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

GOING

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

HCC

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

REGOMUNE

RENOBATE

REGSIN

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

ReDos HCC

RESORCE

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma